Emerging research suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a significant advancement for obesity loss . Initial human trials have demonstrated impressive decreases in visceral tissue, potentially outperforming existing body composition medications . Nevertheless ,